Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

NCT01833143 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Bortezomib
DRUG: Acyclovir

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]